Le Lézard
Classified in: Health
Subject: FDA

LSNE Receives Approval To Manufacture Commercial Aseptic Generic Product At Its Recently Acquired Facility In León, Spain


BEDFORD, N.H., Sept. 30, 2019 /PRNewswire/ -- Lyophilization Services of New England (LSNE), a privately held contract and development manufacturing organization, announces approval of an Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (FDA), for a sterile injectable product manufactured at their aseptic fill finish facility in León, Spain. The facility acquired in June 2019, is approved for US commercial distribution making it LSNE's fourth facility to gain commercial approval.   

Lyophilization Services of New England (PRNewsFoto/Lyophilization Services of...)

Vice President of Quality and Regulatory, Tom McGrath, stated, "We are thrilled with this ANDA approval. LSNE is dedicated to supporting commercial drug manufacturing opportunities at our newest site and building on our commitment to quality, as evidenced by our successful regulatory history." The LSNE-León site is an integral part of LSNE's overall growth strategy of increasing services, capacity and the footprint of its global network.

About LSNE

LSNE is a privately held company with six GMP facilities ? four located in New Hampshire, one in Wisconsin and one located in León, Spain.  LSNE has been providing contract lyophilization services to the pharmaceutical, biotechnology and medical device industries since 1997, specializing in a wide range of services including process development, cGMP fill finish and lyophilization (for vials, pre-filled syringes and dropper bottles for ophthalmics), analytical testing services and regulatory support.  Through the thoughtful integration of six processing facilities, qualified staffing, and an extensive manufacturing history, LSNE is strategically positioned to provide products and services for clinical through commercial supply for pharmaceuticals and medical devices to a multi-national market.

Media Contact
Jeff Clement
Vice President of Business Development
(603) 668-5763
info@lyophilization.com
www.lyophilization.com

SOURCE Lyophilization Services of New England


These press releases may also interest you

at 22:31
CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) updated results from the CS1001-201 trial in a poster presentation at the 2019 American Society of Hematology (ASH) Annual Meeting. CS1001-201 trial is a single-arm, multicenter Phase II...

at 21:07
Following the release of details from a surprise billing agreement between Senate Health, Education, Labor and Pensions (HELP) Committee Chairman Lamar Alexander (R-TN) and House Energy and Commerce Committee Chairman Frank Pallone Jr. (D-NJ) and...

at 21:05
Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the pricing of its underwritten public offering of 11,115,165...

at 20:00
A team led by Stavros Zanos, MD, PhD, assistant professor at the Feinstein Institutes for Medical Research, has published an overview of how bioelectronic medicine may be used to treat pulmonary arterial hypertension (PAH) in the Springer Nature...

at 19:50
North Bud Farms Inc. ("NORTHBUD" or the "Company") is pleased to announce the appointments of Mr. Ryan Brown as Executive Chairman of the Board of Directors, Mrs. Jennifer Ross-Carriere to the Board of Directors and Mr. Sean Homuth as Chief...

at 19:45
UCB, a global biopharmaceutical company, today announced positive results from a Phase II study (TP0001; NCT02718716) of its novel, first-in-class subcutaneous (SC, under the skin) monoclonal antibody, rozanolixizumab, in patients with primary immune...



News published on 30 september 2019 at 13:30 and distributed by: